Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Demyelinating Autoimmune Diseases, CNS Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 7, 2026, 5:16 PM EDT
Active, not recruiting No phase listed Observational

Investigating the Impact of Sex Hormones in Multiple Sclerosis

NCT07081594
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Milap Sandhu
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 7, 2026, 5:16 PM EDT
Not yet recruiting Phase 1 Interventional

Senolytics for Secondary Progressive MS

NCT07270120
View directory record Official record
Conditions
Multiple Sclerosis (MS) Secondary Progressive
Interventions
Dasatinib and quercetin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Applying Speed of Processing Training to Individuals With Multiple Sclerosis

NCT01838824
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Speed of Processing Training
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 7, 2026, 5:16 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 5:16 PM EDT
Recruiting Not applicable Interventional

Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study

NCT07759115
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Music Training Intervention, Music Listening
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 5:16 PM EDT
Active, not recruiting Not applicable Interventional

Remote Therapeutic Monitoring Exercise Tracking

NCT06306768
View directory record Official record
Conditions
Parkinson Disease, Multiple Sclerosis
Interventions
Activity Monitoring
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 7, 2026, 5:16 PM EDT
Withdrawn Phase 1 Interventional

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

NCT02939859
View directory record Official record
Conditions
Multiple Sclerosis, Autoimmune
Interventions
Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
Procedure · Device
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 7, 2026, 5:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Examination of Cognitive Fatigue Using Functional Neuroimaging

NCT04885894
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Zeposia
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 7, 2026, 5:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 7, 2026, 5:16 PM EDT
Active, not recruiting Phase 4 Interventional

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT06180278
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Blood tests, Inebilizumab
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study

NCT03797378
View directory record Official record
Conditions
Spinal Cord Injuries, Traumatic Brain Injury, Spina Bifida, Cerebral Palsy, Stroke, Parkinson Disease, Multiple Sclerosis
Interventions
eM2M
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

NCT00203021
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer acetate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 7, 2026, 5:16 PM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Not applicable Interventional Results available

Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS

NCT04942938
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Neubie
Device
Lead sponsor
CommonSpirit Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 7, 2026, 5:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

NCT01356134
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Genetic Disease Investigators
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Colleyville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

NCT06064539
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tolebrutinib, gemfibrozil, rifampicin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study

NCT04061681
View directory record Official record
Conditions
Multiple Sclerosis, Restless Legs Syndrome
Interventions
Behavioral Intervention (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis

NCT03345199
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Inspiratory Muscle Trainer (IMT)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 7, 2026, 5:16 PM EDT
Completed No phase listed Observational

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

NCT06737419
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 7, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 7, 2026, 5:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

NCT05950308
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 7, 2026, 5:16 PM EDT
Completed No phase listed Observational

MSPT Device Usability Study

NCT02664324
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 7, 2026, 5:16 PM EDT